HollandBIO welcomes Portola as a new member
HollandBIO connects and supports the Dutch biotech industry. We represent over 210 companies in the field of medical, agrifood and industrial biotech. And, HollandBIO is growing steadily. Today, we are proud to announce that Portola Pharmaceuticals joined the HollandBIO community!
medicines aimed at treating thrombosis and haematological malignancies.
Portola was founded in 2003 and was listed on the US NASDAQ in 2013. The company has more than 400 employees, spread over five locations worldwide, of which approximately 50 are in Europe. Portola is headquartered in San Francisco, CA, USA. In mid-2019, Portola started its activities in Europe and opened an office in Amsterdam.
Portola’s first product is Ondexxya (andexanet alfa), the first approved antidote for adult patients undergoing treatment with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) and requiring reversal of anticoagulation due to life-threatening or uncontrollable bleeding. Ondexxya was approved by the EMA in April 2019 and is now available in several European countries, including the Netherlands.